Onconetix Inc (ONCE) Stock News
NASDAQ:ONCE - Nasdaq - - Currency: USD
ONCE Latest News, Press Relases and Analysis
Liver Study Results Show How Crispr Could Transform Treatment
In a milestone for gene therapy, drugmakers Intellia Therapeutics Inc. and Regeneron Pharmaceuticals Inc. reported results from the first clinical trial using Nobel Prize-winning Crispr technology to treat disease inside the human body.
A Perspective On Biopharma's Record M&A Run In 2019
This year was a watershed one for biopharma M&A, with several multibillion-dollar deals announced thus far. M&A activity in 2019 kickstarted with a big deal. Bristol-Myers...
William Blair Maintains Their Hold Rating on Spark Therapeutics (ONCE)
William Blair analyst Raju Prasad maintained a Hold rating on Spark Therapeutics (ONCE – Research Report) today. The company’s shares closed last Monday at $113.57, close to its 52-week high of $114.20. According to TipRanks.com, Prasad is a 5-star analyst with an average return of 25.0% and a 62.3% success rate. Prasad covers the Healthcare
Roche finalizes Spark takeover
Roche (OTCQX:RHHBY) has completed its $114.50/share acquisition of Spark Therapeutics (NASDAQ:ONCE).
Regulators Give Roche Green Light For $4.3B Spark Therapeutics Acquisition
Roche Holding (OTCQX: RHHBY) has received approval from the Federal Trade Commission and Britain’s Competition and Markets Authority to acquire Spark Therapeutics, Inc...
Stocks making the biggest moves premarket: Roku, Boeing, Navistar, Guess, Netflix & more
These are the stocks posting the largest moves before the bell, including Roku, Boeing, Navistar, Guess, Netflix, and more.
U.S. approves Roche-Spark merger
The FTC closes its probe into Roche's (OTCQX:RHHBY) $4.8B acquisition of Spark Therapeutics (NASDAQ:ONCE).The agency won't require any asset sales for the merger to comply with antitrust laws.The FTC
Stocks making the biggest moves midday: Boeing, Micron Technology, Western Digital, WW International
Micron Technology and Western Digital jumped on analyst upgrades while Boeing slid on more uncertainty around the 737 Max jet.
Stocks making the biggest moves premarket: DuPont, Amarin, Boeing, Disney, PG&E, Amgen & more
These are the stocks posting the largest moves before the bell, including DuPont, Amarin, Boeing, Disney, PG&E, Amgen, and more.
Biotech Stocks Burn A Hole In Big Pharma's Pocket. Look For More In 2020
Mergers and acquisitions have lit up biotech stocks, and the hot pace shows no sign of slowing in 2020. Gene therapy and oncology companies are targets.
Week Begins with Biotech Mergers
Week Begins with Biotech Mergers
Merger Monday, Biotech Edition: MRK, SNY, ARQL, THOR & More
Large-cap pharmaceutical companies are putting their assets to work in the biotech space, particularly in cancer treatment (oncology).
Stocks making the biggest moves premarket: ArQule, Merck, Canopy Growth, Macy's, 3M & more
These are the stocks posting the largest moves before the bell, including ArQule, Merck, Canopy Growth, Macy's, 3M, and more.
Europe Markets: European stocks struggle, with drugmakers weaker and Tullow Oil plunging
European stocks were off to a weak start on Monday, as investors appeared to pause after gains late last week triggered by stronger-than-expected U.S. jobs...
Dow Jones Newswires: Roche extends tender offer for Spark Therapeutics
The period for Roche’s offer of $114.50 per share for U.S.-based Spark has been extended several times and was set to expire on Dec. 10.
Mentions: ROG
Astellas’ $3 billion gene therapy deal steadies investors after stalled Roche acquisition
Astellas Pharma Inc.’s $3 billion acquisition of Audentes Therapeutics is a strong indicator that the pharmaceutical industry’s march into gene therapy...
7 Exciting Biotech Stocks to Buy Now
Many of these biotech companies are beating the Nasdaq Biotech Index. With cutting-edge therapies, these are great names to buy.
BioMarin Files MAA to EMA for Gene Therapy of Hemophilia A
BioMarin (BMRN) submits an MAA in Europe for its investigational gene therapy valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
Biogen Ends Enrollment in Eye Disorder Study on Gene Therapy
Biogen (BIIB) completes enrollment in the global phase III STAR clinical study evaluating the gene therapy timrepigene emparvovec for the treatment of a rare, inherited retinal disorder.
Another extension for Roche-Spark takeover offer
Roche (OTCQX:RHHBY) and Spark Therapeutics (NASDAQ:ONCE) have announced yet another extension of the Swiss drugmaker's $4.3B takeover offer for the U.S. gene therapy specialist as regulatory reviews i
Will Spark Therapeutics (ONCE) Report Negative Q3 Earnings? What You Should Know
Spark Therapeutics (ONCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Roche extends offer for Spark shares to November 25
Allowing additional time for U.S. and UK regulators to sign off on the merger, Roche (OTCQX:RHHBY) has extended its tender offer for all outstanding shares of Spark Therapeutics (NASDAQ:ONCE) to Novem
Why Roche's Acquisition Of Spark May Be Complete By Year's End
Roche's acquisition of Spark, a gene therapy fim, will likely close by year's end, an analyst said after reports indicated the FTC would clear the deal.
Mentions: QURE
Best & Worst Performing Mid Cap Stocks for October 24, 2019
UFPI – UFPI leads the way today as the best performing mid cap stock, closing up 19.59%.
Gene Therapy Stocks Rocket On Rumor Roche Clinched Its Spark Buyout
Shares of gene therapy biotech companies launched Thursday on rumors the U.S. Federal Trade Commission cleared Roche's takeover of Spark Therapeutics.
Mentions: QURE
Dow Jones Newswires: U.K.’s competition watchdog opens probe into Roche takeover of Spark Therapeutics
The regulator said it is looking into whether the deal will result in a substantial lessening of competition, and has set Dec. 16 as its deadline to decide...
Roche Posts Solid Sales for First 9 Months of '19, Ups View
Roche (RHHBY) reports strong sales in the first nine months of 2019 and raises guidance.
Roche Boosts Outlook For Third Time In 2019 And Confirms Spark Buyout
Roche boosted its full-year guidance on Wednesday and confirmed its takeover of biotech Spark is on track for yearend. But Roche stock slipped early.